DiscoverACCEL Lite: Featured ACCEL Interviews on Exciting CV ResearchACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report
ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report

ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report

Update: 2023-04-04
Share

Description

In this interim report of extended follow-up of ISCHEMIA, with a total of 557 deaths (nearly twice the number of deaths in the initial phase), the probability of a survival benefit at 7 years with either initial management strategy was not different. These findings provide important evidence for patients with chronic coronary disease and their physicians as they decide whether to add invasive management to guideline-directed medical therapy. 

  In this interview, Judith S. Hochman, MD, FACC, FAHA, William E. Boden MD, FACC, FAHA, and Purvi Parwani MBBS, MPH, FACC, discuss ISCHEMIA-EXTENDed – the Follow-Up Interim Report. 

  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Comments 
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
ACCEL Lite: Optimizing the Care of ASCVD Patients with T2DM

ACCEL Lite: Optimizing the Care of ASCVD Patients with T2DM

2023-04-2516:47

ACCEL Lite: Revascularization of Stable Ischemic Heart Disease in the Era of COURAGE, ISCHEMIA, and ORBITA

ACCEL Lite: Revascularization of Stable Ischemic Heart Disease in the Era of COURAGE, ISCHEMIA, and ORBITA

2023-04-1810:10

ACCEL Lite: Long-Term Secondary Prevention After PCI or MI: Aspirin, Clopidogrel, DAPT or DPI?

ACCEL Lite: Long-Term Secondary Prevention After PCI or MI: Aspirin, Clopidogrel, DAPT or DPI?

2023-04-1308:27

ACCEL Lite: Understanding the Basics of HF-rEF and Work Up

ACCEL Lite: Understanding the Basics of HF-rEF and Work Up

2023-04-1111:58

ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report

ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report

2023-04-0411:50

ACCEL Lite: ACC.23 Late-Breaker: Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk

ACCEL Lite: ACC.23 Late-Breaker: Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk

2023-03-2810:31

ACCEL Lite: When Lifestyle Isn't Enough: Surgical vs. Pharmacological Approaches for Obesity

ACCEL Lite: When Lifestyle Isn't Enough: Surgical vs. Pharmacological Approaches for Obesity

2023-03-2109:58

ACCEL Lite: ACC.23 Late-Breaker: Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy: Primary Results of the LIVE-HCM Study

ACCEL Lite: ACC.23 Late-Breaker: Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy: Primary Results of the LIVE-HCM Study

2023-03-1409:38

ACCEL Lite: Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial

ACCEL Lite: Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial

2023-03-0712:35

ACCEL Lite: From JACC: CACS Improves Risk Prediction in Patients with Suspected Obstructive CAD

ACCEL Lite: From JACC: CACS Improves Risk Prediction in Patients with Suspected Obstructive CAD

2023-02-2808:25

ACCEL Lite: PRECISE – Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected CAD

ACCEL Lite: PRECISE – Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected CAD

2023-02-2112:02

ACCEL Lite: IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in HFrEF

ACCEL Lite: IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in HFrEF

2023-02-1410:24

PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD

PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD

2023-02-0708:28

ACCEL Lite: AHA Late-Breaker: PROGRESSIVE-AF – The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression

ACCEL Lite: AHA Late-Breaker: PROGRESSIVE-AF – The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression

2023-01-3108:14

AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA

AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA

2023-01-2410:27

AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and CV Outcomes in Patients with CKD

AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and CV Outcomes in Patients with CKD

2023-01-1711:50

AHA Late-Breaker: TRANSFORM-HF – Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results

AHA Late-Breaker: TRANSFORM-HF – Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results

2023-01-1009:46

ACCEL Lite: Top Takeaways from 2022: General Cardiology with Glenn Hirsch MD

ACCEL Lite: Top Takeaways from 2022: General Cardiology with Glenn Hirsch MD

2022-12-2215:40

ACCEL Lite: Top Takeaways from 2022: Preventive Cardiology with Martha Gulati MD

ACCEL Lite: Top Takeaways from 2022: Preventive Cardiology with Martha Gulati MD

2022-12-2015:00

ACCEL Lite: Top Takeaways from 2022: Interventional Cardiology with Dipti Itchhaporia MD

ACCEL Lite: Top Takeaways from 2022: Interventional Cardiology with Dipti Itchhaporia MD

2022-12-1316:07

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report

ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report